Diagnostic and Prognostic Evaluation of Vasorin During Septic Shock
NCT07203833
Biomarker, Infection
Amiens, France
View Trial DetailsNCT Number: NCT06539234
Shock is a life-threatening condition which can cause multiple organ failure and even death. One characteristic of shock is low blood pressure which is managed with drugs called vasopressors. Most frequently used vasopressors are noradrenaline, vasopressin and recently also angiotensin II. Angiotensin II is present in the body and has a physiological role in maintaining blood pressure in healthy persons. Renin is an enzyme and a key factor in angiotensin II production in the body. In patients with shock, there is a lack of angiotensin II and an excess of renin in the body. Due to the literature renin has the potential to be a marker of severity of shock. Synthetic angiotensin II is used in patients with shock in whom we cannot normalize the blood pressure with noradrenaline and vasopressin. Regarding scientific data, the use of synthetic angiotensin II reduces the dose of noradrenaline and vasopressin and the incidence of acute kidney injury. The aim of our study is to find out what is the relation between the concentration of renin before and 6 hours after the start of using angiotensin II in patients with shock and their clinical outcome. Since not all patients with shock are responding to angiotensin II, the aim of our study is also to find out which patients could benefit most from synthetic angiotensin II.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Medical ICU, University Medical Centre Maribor, Maribor, Slovenia
In patients with distributive shock (≥18 years) with noradrenaline >0,3 mcg/kg/min and vasopressin >0,03 IE/min not achieving an appropriate mean arterial pressure (65-85 mmHg) an angiotensin II infusion will be started at 20 ng/kg/min and after that adjusted to a max dose of 40 ng/kg/min if needed. Before the infusion and 6 hours after the start of angiotensin II infusion a blood sample will be drawn to determine the renin concentration. The primary outcome will be organ failure free days and ICU free days. Secondary outcome will be the need for vasopressors, dialysis, mechanical ventilation, trend of renin concentration.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 0-30 days
days alive without the need of vasopressors, ventilators, or dialysis
Time frame: 0-30 days
30 minus the number of days in the ICU
Time frame: 0-30 days
time in which vasopressors are needed
Time frame: 0-30 days
time of mechanical ventilation (invasive and/or noninvasive)
Time frame: 0-30 days
time of eventual need for dyalisi´s
Time frame: 0-6 hours
renin concentration before and 6 hours after the start of angiotensin II infusion
Contact information is provided by the study sponsor or research team.
University Medical Centre Maribor
Other
Angiotensin II Stress Test. Renin Kinetics During Treatment of Vasoplegic Shock With Angiotensin II in Relation to Hemodynamic Response to Treatment With Angiotensin II.
Acronym: TENSINTEST
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07203833
Biomarker, Infection
Amiens, France
View Trial DetailsNCT05931601
Cardiovascular Diseases, Disease Attributes
Copenhagen, Denmark
View Trial DetailsNCT05969275
Infections, Inflammation
Ottawa, Ontario, Canada
View Trial DetailsNCT05922982
Cardiovascular Diseases, Norepinephrine
Amiens, France
View Trial Details